Investor Relations
Next Generation Technology for Novel Therapies
Our mission is to restore lost neurological function and improve quality of life for patients by developing novel neurotherapies in close collaboration with our partners.
Our Solution to an Unmet Medical Need:
The Brain Interchange System
Most existing neuroimplants are limited to either recording or stimulation, with few channels and no closed-loop capability – hindering adaptive therapies. CorTec’s Brain Interchange™ System is a fully implantable, bidirectional BCI designed for long-term human use. It enables real-time interaction with the brain, supporting dynamic, personalized treatments for neurological disorders where current solutions fall short.
By addressing the limitations of conventional implants, CorTec’s technology opens new possibilities for restoring function in patients with severe motor impairments and other neurological conditions.
Recent Milestone: First In Human Implantation
In July 2025, CorTec achieved a historic milestone: the first-ever human implantation of a fully implantable, German-developed Brain-Computer Interface (BCI) system. This breakthrough positions CorTec as a global leader in implantable neurotechnology.
The procedure was performed at Harborview Medical Center in Seattle as part of an FDA-approved clinical trial led by researchers from the University of Washington and UCLA. The study targets motor recovery in stroke patients, marking a major leap forward in neurorehabilitation.
The CorTec Brain Interchange™ System is a next-generation, adaptive closed-loop BCI designed to sense, interpret, and stimulate brain activity in real time. For the first time, patients with severe paralysis may regain motor function through intelligent neuromodulation.
You want to know more about CorTec?
Investors Highlights
The successful first-in-human implantation of the CorTec Brain Interchange™ System unlocks a €2.5 billion market opportunity in neurorehabilitation across the US and Europe. This milestone sets a new benchmark for adaptive, closed-loop neuromodulation and positions CorTec at the forefront of next-generation brain therapies.
Beyond stroke rehabilitation, our technology platform is designed to address a broad range of neurological indications, making it a strong contender in the rapidly growing global Brain-Computer Interface (BCI) market. With increasing demand for intelligent neurotechnologies, CorTec is uniquely positioned to capture significant value in both therapeutic and assistive BCI applications.
To realize the full potential of this breakthrough, we are seeking partners who share our vision and want to be part of this transformative journey. Your investment can help bring a novel medical technology to the people who need it most. Discover how you can support the future of neuroscience.
Our Current Investors and Funding
CorTec is supported by a strong investor base, including Santo Venture Capital (Strüngmann family) and LBBW Venture Capital, alongside long-standing private backers. Public funding from the German Federal Ministry of Education and Research (BMBF) and the European Union further accelerates our innovation and clinical development.
Investors
In addition to significant public funding, CorTec has raised 4 rounds of financing.
We proudly introduce you to our current investors.
Mangold Invest
Mangold Invest bundles the industrial investments of the Mangold family (Stuttgart) under the management of Prof. Dr. Klaus Mangold and Dr. Christoph Mangold. Mangold Invest follows a long-term investment approach in the areas of private equity, real estate as well as agriculture and forestry. All investments are led personally and the management is either directly supported or guided over an active advisory board.
The company is a subsidiary of Mangold Consulting GmbH which was founded in 2003 by Prof. Dr. Klaus Mangold, a former member of the board of Daimler and chairman of the German Committee on Eastern European Economic Relations (Ostausschuss der deutschen Wirtschaft). Since then, the company advises successfully projects of well-known companies in Europe, Russia and Central Asia and has a distinctive network in German industry as well as in the mentioned regions.
M-Invest
M-Invest is a private investment company founded by Bernhard and Tobias Meder. Bernhard Meder also founded MEDER electronic, a company for switching technology operating wordwide which merged with Standex Electronics in 2012.
M-Invest does not consider itself a mere financial investor. The company also supports young enterprises with an innovative business idea in their marketing, business development, establishment of sales as well as other entrepreneurial know-how.
www.m-invest.eu
KfW
The KfW Banking Group is Germany’s leading financier of SMEs. It provides companies with long-term investment loans as well as with working capital financing loans.
In addition to this, KfW supports innovative companies with special equity capital programs. With the ERP-Start Fund, it acquires a particular interest in young, innovative, and technology-oriented companies with high growth prospects – always together with private venture capital investors and under the same conditions. Both research and product development and the launch of new products, technologies or services are being financed.
www.kfw.de
High-Tech Gründerfonds
High-Tech Gründerfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gründerfonds invests initially 1 million EUR in the seed stage, with the potential for up to a total of EUR 3 million per portfolio company in follow-on financing. High-Tech Gründerfonds has a total fund volume of around EUR 895.5 million.
Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, the Fraunhofer-Gesellschaft, as well as strategic corporate investors including ALTANA, BASF, Bayer, Boehringer Ingelheim, B. Braun, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, Evonik, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, Phoenix Contact, Postbank, Qiagen, RWE Generation SE, SAP, Schufa, SchwarzGruppe, Stihl, Thüga, Vector Informatik, Wacker and Wilh. Werhahn KG. High-Tech Gründerfonds has about EUR 895.5 million under management in three funds (EUR 272 million HTGF I, EUR 304 million HTGF II, Goal: EUR 316,5 million HTGF III).
Santo Venture Capital GmbH
Santo Venture Capital GmbH is the venture arm of ATHOS KG, the family office of the Strüngmann families.
The investment companies of the Strüngmann Family Office pursue a long-term investment approach in the biotech and healthcare sectors.
LBBW Venture Capital
LBBW Venture Capital GmbH is a wholly owned subsidiary of the Landesbank Baden-Württemberg. It offers venture capital financing for companies in the sectors IT, industrial technologies and life science. In addition to this, it administers the “Seedfonds BW” (seed fund Baden-Württemberg) together with the Mittelständische Beteiligungsgesellschaft Baden-Württemberg GmbH (MBG), specifically financing innovative start-up technology companies from Baden-Württemberg in cooperation with High-Tech Gründerfonds.
K & S W Invest
The K & S W Invest GmbH mainly works as a seed investor for internationally oriented German companies in the field of medical engineering. Klaus Würtenberger, who was already responsible for shaping the development of Berlin Heart GmbH as chairman and partner from 2001 to 2007, is the CEO of K & S W Invest. Klaus Würtenberger is also an accredited coach for High-Tech Gründerfonds, Bonn, and BWcon, Stuttgart.
